Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 01 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding the receipt of an Establishment Inspection Report from the USFDA for its transdermal manufacturing facility in Ahmedabad. The inspection took place in July and the facility has been classified as Voluntary Action Indicated. This announcement serves as a disclosure in accordance with regulatory requirements.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases